BNTX BioNTech
- 86.270
- -2.170-2.45%
- 85.990
- -0.280-0.32%
BioNTech News
FDA Puts Partial Clinical Hold on BioNTech's ADC Trial After Fatalities
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
CCORF analyst John Newman maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $171.According to TipRanks data, the analyst has a success rate of 39.0% and a total averag
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $146
BofA Securities analyst Tazeen Ahmad maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $146.According to TipRanks data, the analyst has a success rate of 48.3% and a t
US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial
BioNTech's (22UA.F) partner MediLink Therapeutics (Suzhou) notified the company that the US Food and Drug Administration placed a partial hold on new patient enrollment for a phase 1 trial assessing i
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Express News | BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202
Sector Update: Health Care Stocks Ease in Afternoon Trading
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) fel
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's (NASDAQ:BNTX) partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading
Bank stocks were helping European equities traded in the US as American depositary receipts nudge marginally higher late Monday morning, rising 0.047% to 1,409.42 on the S&P Europe Select ADR Index. F
BioNTech Says US FDA Placed Partial Clinical Hold on Cancer Drug Trial
BioNTech (BNTX) said Monday its partner MediLink Therapeutics has informed the company that the US Food and Drug Administration has placed a partial hold on enrolling new patients in the US for a Phas
Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $101
Morgan Stanley analyst Terence Flynn maintains $BioNTech(BNTX.US)$ with a hold rating, and maintains the target price at $101.According to TipRanks data, the analyst has a success rate of 63.5% and a
BioNTech Partner Medilink Therapeutics Says FDA Has Placed Partial Clinical Hold On Phase 1 Trial Of BNT326/YL202 For Heavily Pre-Treated Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer Or HR+/HER2-Negative Breast Cancer-6K
The partial hold affects the enrollment of new patients in the trial in the U.S. The FDA has shared with MediLink concerns that BNT326/YL202 may, at higher doses, expose human subjects to unreasonable
Express News | BioNTech Shares Are Trading Lower Amid Weakness in Vaccine Makers
Express News | FDA Says On June 13 Updates Advice To Manufacturers Of Covid-19 Vaccines (2024-2025 Formula): If Feasible Use KP.2 Strain Of JN.1-Lineage
FDA Recommends KP.2 Strain Be Used in Updated COVID-19 Shots
Express News | BioNTech SE : JP Morgan Raises Target Price to $94 From $90
The Feinstein Institutes 2024 Ross Prize Awarded to Stanford University's Dr. Michelle Monje
The 11th Annual Ross Prize Symposium will be held June 20 in New York CityMANHASSET, N.Y.--(BUSINESS WIRE)--The Feinstein Institutes for Medical Research has selected Michelle Monje, MD, PhD, from Sta
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending sharply lower late Tuesday morning, falling 1.34% to 1,420.05 on the S&P Europe Select ADR Index. From continental Euro
J.P. Morgan Maintains BioNTech(BNTX.US) With Sell Rating
J.P. Morgan analyst Jessica Fye maintains $BioNTech(BNTX.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 49.2% and a total average return of 4.9% over the past ye
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending modestly lower late Monday morning, declining 0.39% to 1,431.20 on the S&P Europe Select ADR Index. From continental Eu
Analysis
Price Target
No Data
